The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
If there’s a somewhat decent improvement in outcomes in drug vs placebo at 90 days, that’d be great HT results. People would take it if they test positive to reduce severity of long covid symptoms or reduce the probability of suffering from long covid in the first place. I guess that’s what we’re hoping for here.
I saw RM’s comments as speculation based on what happened with COPD & asthma. There should be a positive effect but it’s likely it won’t be as large as 79%. Hospital trial looked at people with symptoms for 10 days compared to the home trial which looked at people who had symptoms for 7 days or less so we may not see a crazy reduction from 79%.
8 UK sites, 1 US site, 4 Belgian sites active
9 sites waiting to go in Spain
India & France have given P3 the green light
Really not sure what’s happening with the 5 Serbian sites or any of the other countries
Given that P3 recruitment ends next month, it’s very important the number of active sites increases as much as possible, I guess we’re doing ok though on this front.
Eli Lilly’s treatment Activ 2 data was released after 9 weeks, we’ve just about completed week 7 so it’d be nice to see Activ 2 results on week commencing 19th April. That’d work out quite nicely for us given that April 19 is day 90 for the final patient on the home trial.
I know this simple comparison of Eli Lilly’s timeline and ours probably isn’t a fair one but it’s a nice thought imo.
Feel free to correct and/or critique me.